Search academic texts

Information × Registration Number 0215U004923, 0115U004866 , R & D reports Title Landomycin A - novel medicine for chemotherapy of drug-resistant tumors: production, preclinical studies, marketing popup.stage_title Head Stoika Rostyslav Stepanovych, Registration Date 22-12-2015 Organization Institute of Cell Biology NAS of Ukraine popup.description2 Preclinical studies of therapeutic action of promising antitumor antibiotic landomycin A towards experimental models of melanoma B16 and its B16/adr doxorubicin-resistant subline in mice have been carried out. It is shown that landomycin A shows 2-fold higher therapeutic activity on B16/adr melanoma model compared with known anticancer drug doxorubicin, and shows fewer side effects on normal tissues and organs of mice. It was revealed that early production of hydrogen peroxide, produced during landomycin A entry into tumor cells followed with mitochondria-independent activation of effector caspase-7 are main hallmarks of landomycin A ability to overcome acquired resistance of tumor cells to chemotehrapy treatment. The obtained results indicate on a great promise of landomycin A application as a second-line defense drug in treatment of drug-resistant tumor in clinics. Product Description popup.authors Панчук Ростислав Русланович popup.nrat_date 2020-04-02 Close